https://www.valeris.com/insights-data/https://www.valeris.com/insights-data/strategy-consultinghttps://www.valeris.com/insights-data/market-access-intelligencehttps://www.valeris.com/patient-support/https://www.valeris.com/patient-support/access-affordabilityhttps://www.valeris.com/patient-support/free-goods-pharmacyhttps://www.valeris.com/patient-support/nursing-supporthttps://www.valeris.com/patient-support/engagement-adherencehttps://www.valeris.com/patient-support/eserviceshttps://www.valeris.com/patient-support/virtual-clinical-trial-supplyhttps://www.valeris.com/hcp-engagement/https://www.valeris.com/hcp-engagement/contract-saleshttps://www.valeris.com/hcp-engagement/field-reimbursementhttps://www.valeris.com/hcp-engagement/medical-science-liaisonshttps://www.valeris.com/hcp-engagement/clinical-nurse-educatorshttps://www.valeris.com/hcp-engagement/institutional-sales-supporthttps://www.valeris.com/leadership/robert-truckenmiller/https://www.valeris.com/leadership/scott-dulitz/https://www.valeris.com/leadership/joe-abdalla-bio/https://www.valeris.com/leadership/manish-goel/https://www.valeris.com/leadership/peter-formisano/https://www.valeris.com/leadership/jonathan-savage/https://www.valeris.com/leadership/rob-brown/https://www.valeris.com/leadership/karen-russell/https://www.valeris.com/leadership/patrick-lee/https://www.valeris.com/leadership/jodi-dickinson/https://www.valeris.com/leadership/cindy-padgett-jd/https://www.valeris.com/leadership/tim-ogren/https://www.valeris.com/leadership/megan-thomas/https://www.valeris.com/resources/how-policy-reporter-by-valeris-is-using-ai-to-scale-insight-accuracy-and-efficiency/https://www.valeris.com/resources/formulary-suite-understand-formulary-positioning-shape-access-strategy/https://www.valeris.com/resources/valeris-industry-report-is-your-brand-impacted-by-medical-benefit-maximizers/https://www.valeris.com/resources/redesigning-rare-disease-patient-access-a-case-study-in-nephrology/https://www.valeris.com/resources/triangle-insights-group-by-valeris-announces-appointment-of-erin-solano-to-partner/https://www.valeris.com/resources/part-2-innovators-in-affordability-the-intelligence-behind-patient-access/https://www.valeris.com/resources/building-the-use-case-re-evaluating-our-most-demanding-workflows-through-the-patients-eyes/https://www.valeris.com/resources/code-watch-stay-ahead-with-code-specific-coverage-alerts/https://www.valeris.com/resources/trumprx-is-reshaping-access-valeris-is-pharmas-strategic-partner/https://www.valeris.com/resources/valeris-patient-affordability-marks-another-innovation-milestone-by-being-first-to-address-medical-benefit-maximizer-impact/https://www.valeris.com/resources/medical-covered-lives-updates-for-q4-2025/https://www.valeris.com/resources/building-the-use-case-how-signal-detection-aligns-with-fdas-push-for-real-time-reporting/https://www.valeris.com/resources/building-the-use-case-taking-demand-planning-from-retrospective-to-predictive/https://www.valeris.com/resources/valeris-reports-strong-performance-and-significant-milestones-in-fiscal-year-2025/https://www.valeris.com/resources/innovators-in-affordability-the-intelligence-behind-patient-access/https://www.valeris.com/resources/building-the-use-case-the-potential-for-ai-assistants-to-shorten-pharmacy-call-times/https://www.valeris.com/resources/early-2026-results-show-the-value-of-smarter-affordability-strategies/https://www.valeris.com/resources/new-payer-landscape-insights-bcg-unresponsive-nmibc-treatment-coverage/https://www.valeris.com/resources/building-the-use-case-the-potential-for-ai-to-augment-care-coordination-for-better-patient-outcomes/https://www.valeris.com/resources/building-the-future-of-healthcare-services-how-innovation-and-partnership-drive-value-creation-at-valeris/https://www.valeris.com/resources/the-risk-of-believing-zero-disruption-in-copay-maximizer-mitigation/https://www.valeris.com/resources/innovating-with-intention/https://www.valeris.com/resources/the-secret-behind-smarter-more-efficient-copay-programs/https://www.valeris.com/resources/powering-an-ai-driven-enterprise-wide-market-access-platform/https://www.valeris.com/resources/medical-covered-lives-updates-for-q3-2025/https://www.valeris.com/resources/PAL-simplify-patient-access/https://www.valeris.com/resources/the-direct-to-patient-channel-in-pharma/https://www.valeris.com/resources/beyond-the-headlines-how-to-cut-through-the-noise-and-put-patients-first/https://www.valeris.com/resources/understanding-drug-tiering/https://www.valeris.com/resources/building-a-connected-patient-ecosystem/https://www.valeris.com/resources/valeris-appoints-manish-goel-chief-technology-officer/https://www.valeris.com/resources/from-reactive-to-proactive-national-health-system-transformation/https://www.valeris.com/resources/valeris-is-advancing-pharmacy-strategy/https://www.valeris.com/resources/rxstudy-card-overview/https://www.valeris.com/resources/rxstudy-card-process/https://www.valeris.com/resources/case-study-Implementing-a-Virtual-Clinical-Trial-Supply-Strategy/https://www.valeris.com/resources/ManufacturerCollaborationSupplyStrategyGlobal/https://www.valeris.com/resources/LocalSourcingSupplyStrategyGlobal/https://www.valeris.com/resources/rxstudy-card-2025-conference-presentation/https://www.valeris.com/resources/15-years-of-rxstudy-card/https://www.valeris.com/resources/rxstudy-card-clinical-supplies-simplified/https://www.valeris.com/resources/sustainability-in-global-clinical-trial-supply/https://www.valeris.com/resources/beyond-efficiency/https://www.valeris.com/resources/streamliningpayercompliance/https://www.valeris.com/resources/rezdifframashtreatment/https://www.valeris.com/resources/valeris-names-jonathan-savage-chief-product-officer/https://www.valeris.com/resources/valeris-expands-strategic-infrastructure-with-launch-of-transformation-office/https://www.valeris.com/resources/valeris-announces-enhancements-to-its-executive-leadership-team/https://www.valeris.com/resources/medical-device-access-in-value-based-care/https://www.valeris.com/resources/biotech-funding-in-2025/https://www.valeris.com/resources/triangle-insights-group-announces-promotion-of-parker-guse/https://www.valeris.com/resources/policy-reporter-by-mercalis-and-accesssync-announce-strategic-partnership-to-transform-market-access-capabilities/https://www.valeris.com/resources/modernizing-patient-support-harnessing-advanced-automation-artificial-intelligence-and-machine-learning-to-improve-efficiency-and-performance-of-psps/https://www.valeris.com/resources/pharmacord-and-mercalis-to-merge-creating-next-generation-platform-to-meet-evolving-needs-of-the-biopharmaceutical-industry/https://www.valeris.com/resources/beyond-the-fine-print-how-healthcare-systems-are-mastering-payer-claims-requirements-to-prevent-revenue-leakage/https://www.valeris.com/resources/medical-covered-lives-key-updates-for-q4-2024/https://www.valeris.com/resources/expanding-market-access-for-urinary-incontinence-treatments/https://www.valeris.com/resources/drug-channels-unlocking-ais-promise-in-patient-support-programs/https://www.valeris.com/resources/beyond-coding-understanding-payer-publications-supporting-the-revenue-cycle/https://www.valeris.com/resources/unlocking-market-access-comparison-of-scs-pns-for-pain-management/https://www.valeris.com/resources/enhancing-market-access-for-fibroscan/https://www.valeris.com/resources/future-of-cgt-manufacturing/https://www.valeris.com/resources/turquoise-health-and-policy-reporter-announce-strategic-data-partnership/https://www.valeris.com/resources/the-evolving-landscape-of-ctdna-testing-payer-coverage/https://www.valeris.com/resources/diabetes-management-evolution/https://www.valeris.com/resources/indirect-impacts-of-the-ira/https://www.valeris.com/resources/pharmaceutical-commercial-forecasting/https://www.valeris.com/resources/policy-reporter-introduces-payer-compliance-dashboard/https://www.valeris.com/resources/unlocking-opportunities-in-healthcare/https://www.valeris.com/resources/the-changing-landscape-of-specialty-pharma-reimbursement-in-2024/https://www.valeris.com/resources/mercalis-launches-with-an-end-to-end-vision/https://www.valeris.com/resources/leveraging-copay-data-driven-insights-to-improve-hcp-engagements/https://www.valeris.com/resources/mercalis-patient-journey-demo-account-management/https://www.valeris.com/resources/mercalis-patient-journey-demo-copay-support-program/https://www.valeris.com/resources/mercalis-patient-journey-demo-clinical-support/https://www.valeris.com/resources/mercalis-patient-journey-demo-field-reimbursement-support/https://www.valeris.com/resources/mercalis-patient-journey-demo-free-goods-program-support/https://www.valeris.com/resources/mercalis-patient-journey-demo-eservices/https://www.valeris.com/resources/mercalis-patient-journey-demo-enrollment/https://www.valeris.com/resources/mercalis-patient-journey-demo-introduction/https://www.valeris.com/resources/navigating-market-access-challenges-in-life-sciences-commericalization/https://www.valeris.com/resources/cell-and-gene-therapy-wrapped-2023-in-review/https://www.valeris.com/resources/why-the-medicare-specialty-threshold-shouldnt-drive-pricing-strategy/https://www.valeris.com/resources/how-policy-reporter-supports-specialty-associations-with-comprehensive-payer-intelligence/https://www.valeris.com/resources/the-2023-partnering-performance-and-reputation-survey-report/https://www.valeris.com/resources/drug-provisions-in-the-inflation-reduction-act-ira/https://www.valeris.com/resources/data-driven-lcm-contracting-strategy-a-case-study/https://www.valeris.com/resources/betting-on-hide-and-seek-with-aav/https://www.valeris.com/resources/applying-stakeholder-understanding-to-design-digital-health-commercial-models/https://www.valeris.com/resources/idn-engagement-strategy-why-all-therapeutics-need-one/https://www.valeris.com/resources/should-enthusiasm-surrounding-antibiotics-be-tempered/https://www.valeris.com/resources/strategic-portfolio-prioritization-in-the-age-of-gene-and-cell-therapy/https://www.valeris.com/resources/the-us-biosimilar-market-do-analysts-have-it-wrong/https://www.valeris.com/resources/pharmaceutical-business-development-transactions-operations/https://www.valeris.com/resources/pharmaceutical-commercial-forecasting-distilling-insights-from-primary-research/https://www.valeris.com/resources/focusing-on-the-market-environment-to-improve-pharmaceutical-revenue-forecasting/https://www.valeris.com/resources/partnering-performance-and-reputation-survey-report-2020/https://www.valeris.com/resources/combination-therapy-in-oncology/https://www.valeris.com/resources/an-early-view-on-nine-aspects-of-the-emerging-gene-editing-market/https://www.valeris.com/resources/closer-to-the-mark-focusing-on-the-market-environment-to-improve-pharmaceutical-revenue-forecasting/https://www.valeris.com/resources/immuno-oncology-breakthrough-but-not-unbounded/https://www.valeris.com/resources/insights-into-the-market-for-infliximab/https://www.valeris.com/resources/out-of-pocket-elasticity-new-situations-highlight-the-importance-of-understanding-patient-responses-to-cost-burden-sharing/https://www.valeris.com/resources/immunology-to-oncology-a-study-of-biosimilar-market-evolution/https://www.valeris.com/resources/licensing-lifeline-one-strategy-for-catching-up-after-the-quarantine-pause/https://www.valeris.com/resources/a-closer-look-payer-treatment-of-prescription-digital-behavior-therapy/https://www.valeris.com/resources/a-closer-look-summary-of-digital-therapeutics-applications-for-diabetes-management/https://www.valeris.com/resources/pharma-services-due-diligence-identifying-the-commercial-factors-impacting-a-successful-private-equity-transaction/https://www.valeris.com/resources/triangle-insights-group-a-mercalis-company/https://www.valeris.com/resources/executive-summary-payer-skepticism-about-digital-therapeutics/https://www.valeris.com/resources/policy-reporter-demystifying-payer-coverage-to-serve-patients/https://www.valeris.com/resources/100-years-of-diabetes-management-evolution/https://www.valeris.com/resources/a-closer-look-prescription-digital-therapeutics-by-the-numbers-payer-survey/https://www.valeris.com/news/valeris-launches-with-a-fully-integrated-vision-for-life-sciences-companies/https://www.valeris.com/news/triangle-insights-group-by-mercalis-strengthens-team-with-hiring-of-new-partner/https://www.valeris.com/news/mercalis-reports-strong-performance-and-significant-milestones-in-fiscal-year-2024/https://www.valeris.com/news/mercalis-announces-ncdp-expansion/https://www.valeris.com/news/turquoise-health-and-policy-reporter-by-mercalis-announce-strategic-data-partnership/https://www.valeris.com/news/policy-reporter-introduces-payer-compliance-dashboard/https://www.valeris.com/news/tigleadershipappointments/https://www.valeris.com/news/meet-us-at-asembia/https://www.valeris.com/news/2023-annual-highlights/https://www.valeris.com/news/mercalisannouncesexpansionofaccessandadherencetechnologies/https://www.valeris.com/news/mercalis-and-triangle-insights-group-announce-executive-leadership-announcements/https://www.valeris.com/news/healthcareprofessionalschangingpreferencespharmaengagement/https://www.valeris.com/news/qa-with-scott-dulitz-ceo-of-mercalis/https://www.valeris.com/news/mercalis-launches-with-an-end-to-end-vision-for-life-sciences-companies/https://www.valeris.com/news/pharma-lawsuit-against-cms-final-rule-manufacturer-coupons-best-price/https://www.valeris.com/news/trialcard-releases-2022-annual-highlights/https://www.valeris.com/news/trialcard-responds-to-ftc-on-harmful-impact-of-pharmacy-benefit-manager-pbm-practices-on-consumers/https://www.valeris.com/news/trialcard-names-scott-dulitz-chief-executive-officer/https://www.valeris.com/news/us-district-court-strikes-down-2023-cms-final-rule-on-pharmaceutical-manufacturer-coupons-and-best-price/https://www.valeris.com/news/solving-the-copay-and-best-price-challenge/https://www.valeris.com/news/trialcard-announces-acquisition-of-triangle-insights-group/https://www.valeris.com/news/2021-co-pay-accumulator-maximizer-and-best-price-insights/https://www.valeris.com/news/trialcard-releases-2021-annual-highlights/https://www.valeris.com/news/trialcard-awarded-contract-with-us-department-of-health-and-human-services/https://www.valeris.com/news/trialcard-announces-strategic-partnership-with-clientpharma/https://www.valeris.com/news/trialcard-named-2-fastest-growing-privately-held-company-in-the-triangle/https://www.valeris.com/news/trialcard-announces-acquisition-of-archer-healthcare/https://www.valeris.com/news/trialcard-named-5-fastest-growing-privately-held-company-in-the-triangle/https://www.valeris.com/news/conducting-patient-access-in-an-evolving-market/https://www.valeris.com/news/trialcard-names-scott-dulitz-president-chief-strategy-officer/https://www.valeris.com/news/trialcard-selects-infinitus-systems-to-automate-payer-contact-center-activity/https://www.valeris.com/news/trialcard-launches-engagehcp/https://www.valeris.com/news/predictive-payer-coverage-solutions-enabling-clients-to-hit-the-ground-running/https://www.valeris.com/news/trialcards-sini-abraham-receives-triangle-business-journals-40-under-40-leadership-award/https://www.valeris.com/news/trialcards-inspiring-hope-campaign-exceeds-fundraising-goal/https://www.valeris.com/news/a-framework-to-optimize-patient-access-and-drive-value-in-the-care-continuum/https://www.valeris.com/news/trialcards-policy-reporter-announces-launch-of-its-coverage-viewerpharmacy-edition/https://www.valeris.com/news/no-rare-disease-patient-goes-forgotten/https://www.valeris.com/news/rare-disease-stopping-at-nothing/https://www.valeris.com/news/tc-script-to-the-rescue/https://www.valeris.com/news/trialcard-reports-third-consecutive-year-of-double-digit-growth/https://www.valeris.com/news/2021-outlook-five-themes-that-will-define-co-pay-assistance/https://www.valeris.com/news/cms-releases-final-rule-impacting-co-pay-assistance-programs-and-best-price/https://www.valeris.com/news/trialcard-reports-42-organic-growth-and-acquires-three-companies-in-2019/https://www.valeris.com/news/trialcards-mango-health-announces-new-interoperable-technology-platform/https://www.valeris.com/news/new-payer-policies-introduce-co-pay-accumulators-to-medical-benefit-products-implications-for-manufacturer-programs/https://www.valeris.com/news/trialcard-announces-acquisition-of-canary-insights/https://www.valeris.com/news/tc-script-navigating-supply-chain-during-covid-19/https://www.valeris.com/news/clinical-supply-time-and-cost-savings/https://www.valeris.com/news/trialcard-submits-comments-opposing-cms-best-price-proposed-rule/https://www.valeris.com/news/massachusetts-study-highlights-co-pay-assistance-as-positively-impacting-patient-access-adherence/https://www.valeris.com/news/co-pay-programs-the-cms-best-price-revision/https://www.valeris.com/news/time-management-in-clinical-trial-supplies/https://www.valeris.com/news/the-2021-notice-of-benefit-and-payment-parameters-the-impact-on-co-pay-programs/https://www.valeris.com/news/payer-intelligence-how-can-it-be-combined-with-technology-to-enhance-patient-access/https://www.valeris.com/news/health-plans-scramble-to-publish-new-policies-on-covid-19-testing-diagnosis-and-treatment/https://www.valeris.com/news/clinical-supply-availability-speed-to-study-start-up/https://www.valeris.com/news/covid-19-a-message-from-president-ceo-mark-bouck/https://www.valeris.com/news/rare-is-mighty-rare-is-exceptional/https://www.valeris.com/news/co-pay-card-fraud-detection-the-role-of-processes-and-people/https://www.valeris.com/news/pharmacy-fraud-within-pharmaceutical-co-pay-programs-what-you-need-to-know/https://www.valeris.com/news/law-and-order-pharmacy-fraud-unit/https://www.valeris.com/https://www.valeris.com/end-to-end-partnership/https://www.valeris.com/news/https://www.valeris.com/resources/https://www.valeris.com/leadership/https://www.valeris.com/contact/https://www.valeris.com/company/https://www.valeris.com/careers/https://www.valeris.com/community/https://www.valeris.com/get-started/https://www.valeris.com/privacy/https://www.valeris.com/terms/https://www.valeris.com/sitemap/